Evidence map›Paper›PMID 32618257›Full record

ArticleThe American journal of tropical medicine and hygiene2020

Case Report: Dynamics of Acquired Fluoroquinolone Resistance under Standardized Short-Course Treatment of Multidrug-Resistant Tuberculosis.

Jean Claude Semuto Ngabonziza, Armand Van Deun, Patrick Migambi, Esdras Belamo Niyigena, Théogène Dusabe, Yves Mucyo Habimana, Bertin Ushizimpumu, Wim Mulders, Tom Decroo, Dissou Affolabi and 3 more

Open access · bronzeAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in The American journal of tropical medicine and hygiene, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.2field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 4 countries.

Jean Claude Semuto Ngabonziza1National Reference Laboratory Division, Department of Biomedical Services, Rwanda Biomedical Centre, Kigali, Rwanda.
Armand Van Deun4Independent TB Consultant, Leuven, Belgium.
Patrick Migambi5Tuberculosis and Other Respiratory Diseases Division, Institute of HIV/AIDS Disease Prevention and Control, Rwanda Biomedical Centre, Kigali, Rwanda.
Esdras Belamo Niyigena1National Reference Laboratory Division, Department of Biomedical Services, Rwanda Biomedical Centre, Kigali, Rwanda.
Théogène Dusabe6MDR-TB Clinic, Kabutare Hospital, Huye, Rwanda.
Yves Mucyo Habimana5Tuberculosis and Other Respiratory Diseases Division, Institute of HIV/AIDS Disease Prevention and Control, Rwanda Biomedical Centre, Kigali, Rwanda.
Bertin Ushizimpumu1National Reference Laboratory Division, Department of Biomedical Services, Rwanda Biomedical Centre, Kigali, Rwanda.
Wim Mulders2Mycobacteriology Unit, Department of Biomedical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.
Tom Decroo7Department of Clinical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.
Dissou Affolabi9Laboratoire de Référence des Mycobactéries, Cotonou, Benin.
Philip Supply10Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019-UMR9017-CIIL-Centre d'Infection et d'Immunité de Lille, F-59000 Lille, France.
Bouke C de Jong2Mycobacteriology Unit, Department of Biomedical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.
Leen Rigouts2Mycobacteriology Unit, Department of Biomedical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.
Instituut voor Tropische Geneeskunde · BERwanda Biomedical Center · RWAidjan-Lagos Corridor Organization · BJInstitut Pasteur de Lille · FRRwanda Military Hospital · RW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We report a case of acquired fluoroquinolone (FQ) resistance under short-course multidrug-resistant tuberculosis (MDR-TB) treatment. The patient was managed at Kabutare hospital, one of the two specialized MDR-TB clinics in Rwanda. A low dose of moxifloxacin was used in the first three critical months. Acquired resistance was identified at the ninth month of treatment, 3 months after stopping kanamycin in a strain initially susceptible only to FQs, kanamycin, and clofazimine. Fluoroquinolone resistance was detected in the same month by deep sequencing as routinely used second-line line probe assay and phenotypic drug susceptibility testing. High-dose FQ, preferably gatifloxacin, should be used to maximize effectiveness.

Indexed as

Antitubercular AgentsClofazimineDrug Resistance, Multiple, BacterialFemaleFluoroquinolonesGatifloxacinGenes, BacterialHigh-Throughput Nucleotide SequencingHumansKanamycinMicrobial Sensitivity TestsMiddle AgedMoxifloxacinMycobacterium tuberculosisRwandaSequence Analysis, DNAAntitubercular AgentsClofazimineFluoroquinolonesGatifloxacinKanamycinMoxifloxacin

Identifiers

PMID32618257
PMCPMC7543851
OpenAlexW3039031110

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.